Research Article
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Table 3
Adverse reactions of the 39 patients with advanced GC who received apatinib plus PD-1 blockade administration.
| | Adverse reactions | Total (, %) | Grades 1-2 (, %) | Grades 3-4 (, %) |
| | Any grade adverse reactions | 38 (97.4) | | 21 (53.8) | | Fatigue | 24 (61.5) | 20 (51.3) | 4 (10.3) | | Nausea and vomiting | 22 (56.4) | 17 (43.6) | 5 (12.8) | | Diarrhea | 19 (48.7) | 16 (41.0) | 3 (7.7) | | Hypertension | 18 (46.2) | 13 (33.3) | 5 (12.8) | | Hand-foot syndrome | 15 (38.5) | 11 (28.2) | 4 (10.3) | | Rash | 11 (28.2) | 9 (23.1) | 2 (5.1) | | AST/ALT elevation | 10 (25.6) | 8 (20.5) | 2 (5.1) | | Proteinuria | 8 (20.5) | 6 (15.4) | 2 (5.1) | | Weight loss | 7 (17.9) | 7 (17.9) | 0 (0.0) | | REECP | 6 (15.4) | 5 (12.8) | 1 (2.6) | | Pneumonia | 4 (10.3) | 4 (10.3) | 0 (0.0) | | Anemia | 3 (7.7) | 3 (7.7) | 0 (0.0) |
|
|
Abbreviations: GC: gastric cancer; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
|
